scholarly journals Reduced Clinical Efficacy of Pazufloxacin against Gonorrhea Due to High Prevalence of Quinolone-Resistant Isolates with the GyrA Mutation

1998 ◽  
Vol 42 (3) ◽  
pp. 579-582 ◽  
Author(s):  
Masatoshi Tanaka ◽  
Tetsuro Matsumoto ◽  
Misao Sakumoto ◽  
Koichi Takahashi ◽  
Takeshi Saika ◽  
...  
Keyword(s):  
Susceptibility Testing ◽  
Oral Dosage ◽  
Antibiotic Susceptibility Testing ◽  
Wild Type ◽  
Gonococcal Urethritis ◽  
Negative Culture ◽  
High Prevalence ◽  
The Mean ◽  
Gyra Mutation

ABSTRACT Forty-two men with gonococcal urethritis were treated with an oral dosage of 200 mg of pazufloxacin, a new fluoroquinolone, three times daily for 3 days. Only 28 of the 42 men (66.7%) had negative culture results for Neisseria gonorrhoeae during follow-up. Of the 42 isolates, 41 could be recultured for antibiotic susceptibility testing and DNA sequencing. In 26 of the 41 isolates (63.4%), GyrA mutations with or without ParC mutations were identified. Among the 26 isolates, 23 contained a single GyrA mutation, 1 contained two GyrA mutations, and 2 contained three mutations including double GyrA and single ParC mutations. A single Ser-91-to-Phe mutation, which was detected in 14 of the 26 isolates, was the most common GyrA mutation, followed by an Ala-75 to Ser mutation and an Asp-95 to Asn or Gly mutation in GyrA. All three isolates with two or three mutations contained the Ser-91-to-Phe GyrA mutation. Eleven of the 14 isolates with the single Ser-91-to-Phe mutation within GyrA and all 3 isolates with two or three mutations persisted after pazufloxacin treatment. On the other hand, all 15 wild-type and 9 mutant isolates with a substitution at codon Ala-75 or Asp-95 were eradicated. The mean MIC of pazufloxacin for mutants with the single Ser-91-to-Phe mutation in GyrA was 66-fold higher than that for the wild type. The results obtained in this study suggest that a high prevalence of fluoroquinolone-resistant gonococcal isolates with the Ser-91-to-Phe mutation in GyrA reduced the efficacy of pazufloxacin as treatment for gonococcal urethritis.

Salmonella enterica serovar Paratyphi A isolated from a hard-to-heal diabetic ulcer: a case report

2020 ◽  
Vol 29 (1) ◽  
pp. 12-15
Author(s):  
Ayomi Dilhari ◽  
Sujatha Pathirage ◽  
Chinthika Gunasekara ◽  
Neluka Fernando ◽  
Deepaka Weerasekara ◽  
...  
Keyword(s):  
Type Ii Diabetes ◽  
Susceptibility Testing ◽  
Type Ii ◽  
Antibiotic Susceptibility Testing ◽  
Delayed Wound Healing ◽  
Diabetic Ulcer ◽  
History Of ◽  
Diabetic Wounds ◽  
Wound Tissue

Chronically infected diabetic wounds have a polymicrobial aetiology. However, Salmonella Paratyphi A is a very rare cause of wound infection. A 76-year-old female patient with type II diabetes presented with a wound on the left leg of two months' duration. The wound was painful, erythematous and a thick, foul-smelling discharge was present. There was a history of delayed wound healing. Salmonella Paratyphi A and Pseudomonas aeruginosa were isolated from the wound tissue. The patient was treated with cefuroxime and cloxacillin empirically and following the antibiotic susceptibility testing (ABST) report, ciprofloxacin was given for 10 days. The wound was treated with multiple debridements and topical antiseptic. On follow-up, the patient remained afebrile with subsiding discharge from the ulcer. This is the first reported case of Salmonella Paratyphi A from an infected diabetic ulcer in Sri Lanka and it serves to further define the spectrum of illnesses caused by this uncommon pathogen.

scholarly journals Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing

2008 ◽  
Vol 52 (9) ◽  
pp. 3092-3098 ◽  
Author(s):  
Marie Desnos-Ollivier ◽  
Stéphane Bretagne ◽  
Dorothée Raoux ◽  
Damien Hoinard ◽  
Françoise Dromer ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Antibiotic Susceptibility ◽  
Susceptibility Testing ◽  
Antifungal Susceptibility ◽  
Clinical Isolates ◽  
Antibiotic Susceptibility Testing ◽  
Wild Type ◽  
European Committee ◽  
Rpmi Medium

ABSTRACT Mutations in two specific regions of the Fks1 subunit of 1,3-β-d-glucan synthase are known to confer decreased caspofungin susceptibility on Candida spp. Clinical isolates of Candida spp. (404 Candida albicans, 62 C. tropicalis, and 21 C. krusei isolates) sent to the French National Reference Center were prospectively screened for susceptibility to caspofungin in vitro by the broth microdilution reference method of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (AFST-EUCAST). Twenty-eight isolates (25 C. albicans, 2 C. tropicalis, and 1 C. krusei isolate) for which the caspofungin MIC was above the MIC that inhibited 90% of the isolates of the corresponding species (MIC90) were subjected to molecular analysis in order to identify mutations in the fks1 gene. Substitutions in the deduced protein sequence of Fks1 were found for 8 isolates, and 20 isolates had the wild-type sequence. Among the six C. albicans isolates harboring mutations, six patterns were observed involving amino acid changes at positions 641, 645, 649, and 1358. For C. tropicalis, one isolate showed an L644W mutation, and for one C. krusei isolate, two mutations, L658W and L701M, were found. Two media, RPMI medium and AM3, were tested for their abilities to distinguish between isolates with wild-type Fks1 and those with mutant Fks1. In RPMI medium, caspofungin MICs ranged from 0.25 to 2 μg/ml for wild-type isolates and from 1 to 8 μg/ml for mutant isolates. A sharper difference was observed in AM3: all wild-type isolates were inhibited by 0.25 μg/ml of caspofungin, while caspofungin MICs for all mutant isolates were ≥0.5 μg/ml. These data demonstrate that clinical isolates of C. albicans, C. tropicalis, and C. krusei with decreased susceptibility to caspofungin in vitro have diverse mutations in the fks1 gene and that AM3 is potentially a better medium than RPMI for distinguishing between mutant and wild-type isolates using the AFST-EUCAST method.

47. NON-CHLAMYDIAL NON-GONOCOCCAL URETHRITIS - MANAGEMENT AND FOLLOWUP DILEMMAS

Sexual Health ◽  
2007 ◽  
Vol 4 (4) ◽  
pp. 302
Author(s):  
N. Edmiston ◽  
C. Ooi
Keyword(s):  
Database Search ◽  
Contact Tracing ◽  
Adequate Treatment ◽  
Gonococcal Urethritis ◽  
Significant Difference ◽  
The Mean ◽  
Antibiotic Cover

Aim: To audit the management of non chlamydial non gonococcal urethritis (NCNGU) for 2006. Method: A clinic database search for cases of non-specific urethritis was conducted. Charts were reviewed and cases subsequently diagnosed with Chlamydia or gonorrhoea at the visit were excluded. One person reviewed the charts for diagnosis, microscopy, treatment, contact tracing and follow up. Results: There were 38 recorded of cases of NCNGU. The mean age of cases was 28.8 years (SD 10.8), all were male,15.8% identified as MSM. Microscopy was performed in 60.5% of cases and PMNLs were detected in 36.8% of all cases (63.6% of cases where microscopy was performed). Treatment was with azithromycin in 63.2% of cases, doxycycline in 28.9% of cases, tinidazole in one case (2.6%) and no treatment was given in one case. Patients with PMNLs on microscopy were significantly more likely to be treated with azithromycin than those without PMNLs on microscopy or with no microscopy done (93.8% vs 50.0%, p < 0.01, x2 test). Contact tracing (CT) was recommended in 17 cases (55.3%) with confirmation of partner treated in 7 cases. There was no significant difference in contact tracing recommendation between those with PMNLs on microscopy and those without or microscopy not done (56.3% vs 36.4%, p > 0.2, x2 test). Clinical follow up at the clinic occurred in 25 cases. 80% (95%CI 60.9%-91.1%) of those followed up had resolution of symptoms, with the remainder having a recurrence or failure of resolution. Discussion: NSU management should include antibiotic cover for possible undetected Chlamydia. Azithromycin was more likely to be used if PMNLs were detected. Chlamydia treatment occurred in all but two cases, with one of the two cases having had adequate treatment previously. New Australian CT guidelines recommend CT M. genitalium but not for NSU. We would recommend CT current or most recent partners in all cases of NCNGU.

252. Morphometric and histological analysis of ovaries from sheep heterozygous for the prolific woodlands allele

2005 ◽  
Vol 17 (9) ◽  
pp. 101
Author(s):  
E. S. Feary ◽  
J. L. Juengel ◽  
P. Smith ◽  
A. R. O'Connell ◽  
G. H. Davis ◽  
...  
Keyword(s):  
Histological Analysis ◽  
Follicular Development ◽  
Wild Type ◽  
Preantral Follicles ◽  
Antral Follicles ◽  
Mechanistic Pathway ◽  
Morphometric Methods ◽  
The Mean ◽  
Large Ovary

Woodlands are a line of Coopworth sheep with a novel, imprinted X-linked fecundity allele resulting in ovulation rates about 0.40 higher than wild-type animals. Daughters of progeny tested sires with and without the gene were studied. Previously, lambs heterozygous for the Woodlands allele were found to have larger ovaries and more antral (i.e. type 5) but not preantral (i.e. types 1–4) follicles than in wild-type contemporaries. The large ovary phenotype was found to be transient and was absent after puberty. However, based on follow-up studies it was evident that the large ovary phenotype was not strongly associated with the Woodlands fecundity allele. Thus, it was uncertain whether animals carrying the Woodlands gene had different follicular populations compared to wild-type controls. To address this question, follicular populations were compared in adult ewes heterozygous for the Woodlands allele with age-matched controls. Using standard morphometric methods and histological analysis, no differences were observed in the mean numbers of types 1, 1a, 2, 3 and 4 preantral follicles between the genotypes. Furthermore, no differences were observed between genotypes in follicular or oocyte diameters for any follicular type. The adult Woodlands carrier ewes had twice as many small type 5 follicles (< 1mm) when compared to wild-type contemporaries although no difference was seen in the numbers of antral follicles > 1mm in diameter. In addition, antrum formation occurred at a smaller follicular diameter in the heterozygous Woodlands animals. Therefore, the increased number of antral follicles observed in both lambs and adult ewes suggests that this difference in pattern of follicular development is associated with the X-linked fecundity allele. This novel phenotype of early antrum formation and larger number of small preantral follicles differs from that observed in sheep with the Inverdale or Booroola mutations, suggesting that a different mechanistic pathway is involved. Acknowledgements: The Marsden Fund, FRST and Ovita.

scholarly journals CPX-351 for Acute Myeloid Leukaemia: Real World Results Are Comparable to Trial Outcomes and Exceeds Them in Non-Adverse Risk Patients- a Multicentre Experience from West Midlands Hospitals on Behalf of West Midlands Research Consortium ( WMRC) UK

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4416-4416
Author(s):  
Vidhya Murthy ◽  
Richard Whitmill ◽  
Clare Lodwick ◽  
Peter Dyer ◽  
Maria Ahmed ◽  
...  
Keyword(s):  
Median Survival ◽  
Real World ◽  
Remission Rate ◽  
Wild Type ◽  
Neutrophil Recovery ◽  
Secondary Aml ◽  
Original Trial ◽  
West Midlands ◽  
The Mean

Abstract Patients with secondary AML or MDS derived AML have poor outcomes compared to de-novo AML. The benefits of intensive chemotherapy without anticipated transplant consolidation have been previously doubted. Outcomes in USA trial centres have not often been closely replicable in real world settings. From November 2018 CPX-351 has been available in the UK for secondary AML, therapy related AML, AML with MDS related Karyotype (AML-MRC) and licensed but not funded for AML with myelodysplastic related changes. Objectives Here we report our experience specifically on patient outcomes and toxicity across 5 Hospitals in West Midlands, UK Methods Patients receiving CPX 351 outcomes were evaluated retrospectively from 2018 to 2021. Baseline genetics, CPX 351 indications, patient's comorbidities, overall survival, remission status, number of cycles delivered, early mortality, reasons for early discontinuation, intensive care admission and time for neutrophil recovery (&gt;0.5) was recorded. Time-to-event outcomes reported here are from a data cut on 01-06-21 Results In a total cohort of 57 patients baseline characteristics are shown on table 1 and compared with the original trial CPX-351 group. Median follow up was 376 days (range 21 to 1248 days). The mean age was 63, 17 patients were under 60, 31 males and 26 females. The most common indication for CPX-351 was AML with antecedent MDS/MPN 51% (N=29), therapy related 14% (N=8), MDS related karyotype (AML-MRC) 19% (N=11) and 16% (N=9) other patients. Mean Charleston co-morbidity score was 2.7 (range 0-6), 10.5% (N=6) had previous non myeloid malignancies, 8.7% (N=5) had prior ischaemic heart disease, only 3.5% (N=2) had ejection fractions under 50%. The most common mutations were TP53 21% (N=12), ASXL1 15.7% (N=9), TET2 15.7% (N=9), IDH2 10.5% (N=6), RUNX1 10.5% (N=6), SRSF2 7% (N=4), JAK2 3.5% (N=2), FLT3 5% (N=3), NPM1 5%(N=3) and IDH1 5% (N=3). MRC cytogenetic risk was adverse in 19 patients (33%), intermediate in 35 patients (61%) and favourable in 3 patients (5%). 30 patients (53%) had adverse European Leukaemia Network classification, 17 (30%) had intermediate and 10 (17%) had favourable. 30-day mortality was 3/57 (5%), 60-day mortality was 6 (10.5%) comparable to the 5.9% and 10.6% rates for the original trial. 9% or 5/57 patients were admitted to ITU with 2 survivors beyond 60 days. Neutropenic fever requiring antibiotics was 100% whereas only 5/57 (9%) had radiological evidence of fungal infection. Only one patient died from COVID 19. The mean time to neutrophil recovery was 35 days with a range of 12 to 84 days. 29 patients completed 1 cycle, 25 completed 2 cycles, only 3 completed 3 cycles. The reasons for stopping were death, refractory disease, drop in performance status, alternative chemotherapy chosen or moving to transplantation (39%). Composite remission rate including CRi was 61% 36/57, adverse ELN group demonstrated 50% 15/30, intermediate 76% 13/17 and favourable 80% 8/10. Mutated P53 was associated with a 50% 6/12 rate whereas in wild type P53 the remission rate was 60% 30/45. Overall median survival from diagnosis was 429 days [95% CI 274 to 788 days]. To compare with the original trial, we removed the under 60s and those with less than 1 year follow up, in this cohort of 30 patients the median survival was 289 days (9.5 months) with 95% CI of 255 to 476 days. P53 mutated patients had an estimated median survival of 257 days versus wild type p53 with 524 days hazard ratio of 2.418 (CI 1.077 to 5.248) with p value of 0.032. Median survival for ELN groups was 373 days (adverse), 413 days (intermediate) and not reached for favourable. Of the 36 patients who achieved a remission, 22 went on to receive an allogenic transplant with follow from 254 to 1248 days, median survival estimated 706 days (95% CI 429-not reached). Patients in remission who haven't received a transplant have a similar estimated survival of 788 days (305-not reached) pending longer follow up. Conclusion This is the first UK multicentre analysis to show comparable results to the landmark trial (median survival 9.5 months in equivalent cases). The improved overall remission rate 61% versus the 47% in the trial and the longer median survival 14 months versus 9.5 months in the trial is expected given the younger age and increase in favourable risk genetics. This study therefore supplies further data of CPX-351 efficacy in younger patients not included in the original studies and may now be used as a standard comparator arm. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum

Microbiology ◽  
2004 ◽  
Vol 150 (9) ◽  
pp. 2947-2958 ◽  
Author(s):  
Michael E. Watson ◽  
Jane L. Burns ◽  
Arnold L. Smith
Keyword(s):  
Cystic Fibrosis ◽  
Haemophilus Influenzae ◽  
Multilocus Sequence Typing ◽  
Susceptibility Testing ◽  
Antibiotic Susceptibility Testing ◽  
Enterobacterial Repetitive Intergenic Consensus ◽  
Bacterial Populations ◽  
Cystic Fibrosis Sputum ◽  
Genetic Fingerprint ◽  
High Prevalence

Hypermutable bacterial pathogens exist at surprisingly high prevalence and benefit bacterial populations by promoting adaptation to selective environments, including resistance to antibiotics. Five hundred Haemophilus influenzae isolates were screened for an increased frequency of mutation to resistance to rifampicin, nalidixic acid and spectinomycin: of the 14 hypermutable isolates identified, 12 were isolated from cystic fibrosis (CF) sputum. Analysis by enterobacterial repetitive intergenic consensus (ERIC)-PCR and ribotyping identified eight distinct genetic fingerprints. The hypermutable phenotype of seven of the eight unique isolates was associated with polymorphisms in conserved sites of mutS. Four of the mutant mutS alleles were cloned and failed to complement the mutator phenotype of a mutS : : TSTE mutant of H. influenzae strain Rd KW20. Antibiotic susceptibility testing of the hypermutators identified one β-lactamase-negative ampicillin-resistant (BLNAR) isolate with two isolates producing β-lactamase. Six isolates from the same patient with CF, with the same genetic fingerprint, were clonal by multilocus sequence typing (MLST). In this clone, there was an evolution to higher MIC values for the antibiotics administered to the patient during the period in which the strains were isolated. Hypermutable H. influenzae with mutations in mutS are prevalent, particularly in the CF lung environment, and may be selected for and maintained by antibiotic pressure.

Impact of K-ras status on FOLFOX and XELOX regimens efficacy in metastatic colorectal (mCRC) patients (pts).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e14674-e14674
Author(s):  
Mikhail Fedyanin ◽  
Alexey Tryakin ◽  
Ilya Pokataev ◽  
Igor Bazin ◽  
Vechaslav Aliev ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Predictive Value ◽  
Prognostic Significance ◽  
Pcr Analysis ◽  
Wild Type ◽  
End Point ◽  
Type K ◽  
Ras Status ◽  
The Mean

e14674 Background: Predictive value of K-ras status for the treatment with anti-EGFR monoclonal antibodies is well established. There is a lack of data about predictive significance of K-ras status for oxaliplatin-based chemotherapy (CT). We retrospectively studied prognostic and predictive significance of mutant K-ras in mCRC pts treated with FOLFOX or XELOX in 1st line CT. Methods: We analyzed data on 127 pts with mCRC, who were treated in our department during 2008-2011 with oxaliplatin-based regimens. K-ras status was determined by PCR analysis in 51/127 (40,1%) pts. Mutant K-ras was detected in 16/51 (31,3%) pts: 13/16 (81,3%) – codon 12, 3/16 (18,7%) – codon 13. mFOLFOX6 was administered in 21/51 (41,2%), XELOX – in 30/51 (58,8%) pts. No pts received anti-EGFR mAb in the 1-st line. Median follow-up was 9 months (range, 2 - 41). The mean number of courses was 9 and 5 in FOLFOX and XELOX groups, respectively. PFS was chosen as a primary end-point. Results: Median PFS was 7,5 months for all 127 pts, 8,4 months in pts with FOLFOX and 7,5 months in pts with XELOX. Median PFS in pts with wild type K-ras was 10,3 months and 6,5 months in pts with mutant K-ras (p=0,1, HR 1,7, 95%CI 0,9-3,4). Negative prognostic significance of mutant K-ras was seen in XELOX group (PFS, 10,9 vs 5,7 months, р= 0,002) but not in FOLFOX group (PFS, 7,7 vs 9,3 months, р= 0,48). In pts with wild type K-ras XELOX lead to longer PFS than FOLFOX regimen - 10,9 vs 7,5 months, respectively (р=0,09, HR 0,52, 95%CI 0,23-1,14). And vice versa, in pts with mutant K-ras FOLFOX was more active than XELOX – median PFS was 9,3 vs 5,7 months, respectively (р=0,009, HR 0,3, 95%CI 0,05-0,64). Conclusions: Our findings probably suggest that K-ras status influences the efficacy of FOLFOX and XELOX regimens in mCRC pts. These data need to be confirmed in larger series of pts.

scholarly journals Validation of Antibiotic Susceptibility Testing Guidelines in a Routine Clinical Microbiology Laboratory Exemplifies General Key Challenges in Setting Clinical Breakpoints

2014 ◽  
Vol 58 (7) ◽  
pp. 3921-3926 ◽  
Author(s):  
Michael Hombach ◽  
Patrice Courvalin ◽  
Erik C. Böttger
Keyword(s):  
Antibiotic Susceptibility ◽  
Susceptibility Testing ◽  
Clinical Microbiology Laboratory ◽  
Large Set ◽  
Antibiotic Susceptibility Testing ◽  
Wild Type ◽  
General Importance ◽  
Key Issues ◽  
Clinical Breakpoints ◽  
Species Specific

ABSTRACTThis study critically evaluated the new European Committee for Antimicrobial Susceptibility Testing (EUCAST) antibiotic susceptibility testing guidelines on the basis of a large set of disk diffusion diameters determined for clinical isolates. We report several paradigmatic problems that illustrate key issues in the selection of clinical susceptibility breakpoints, which are of general importance not only for EUCAST but for all guidelines systems, i.e., (i) the need for species-specific determinations of clinical breakpoints/epidemiological cutoffs (ECOFFs), (ii) problems arising from pooling data from various sources, and (iii) the importance of the antibiotic disk content for separating non-wild-type and wild-type populations.

scholarly journals Standardization of Operator-Dependent Variables Affecting Precision and Accuracy of the Disk Diffusion Method for Antibiotic Susceptibility Testing

2015 ◽  
Vol 53 (12) ◽  
pp. 3864-3869 ◽  
Author(s):  
Michael Hombach ◽  
Florian P. Maurer ◽  
Tamara Pfiffner ◽  
Erik C. Böttger ◽  
Reinhard Furrer
Keyword(s):  
Antibiotic Susceptibility ◽  
Susceptibility Testing ◽  
Disk Diffusion ◽  
Diffusion Method ◽  
Antibiotic Susceptibility Testing ◽  
Content Type ◽  
E Coli ◽  
The Mean ◽  
Precision And Accuracy ◽  
Standard Deviations

Parameters like zone reading, inoculum density, and plate streaking influence the precision and accuracy of disk diffusion antibiotic susceptibility testing (AST). While improved reading precision has been demonstrated using automated imaging systems, standardization of the inoculum and of plate streaking have not been systematically investigated yet. This study analyzed whether photometrically controlled inoculum preparation and/or automated inoculation could further improve the standardization of disk diffusion. Suspensions ofEscherichia coliATCC 25922 andStaphylococcus aureusATCC 29213 of 0.5 McFarland standard were prepared by 10 operators using both visual comparison to turbidity standards and a Densichek photometer (bioMérieux), and the resulting CFU counts were determined. Furthermore, eight experienced operators each inoculated 10 Mueller-Hinton agar plates using a single 0.5 McFarland standard bacterial suspension ofE. coliATCC 25922 using regular cotton swabs, dry flocked swabs (Copan, Brescia, Italy), or an automated streaking device (BD-Kiestra, Drachten, Netherlands). The mean CFU counts obtained from 0.5 McFarland standardE. coliATCC 25922 suspensions were significantly different for suspensions prepared by eye and by Densichek (P< 0.001). Preparation by eye resulted in counts that were closer to the CLSI/EUCAST target of 108CFU/ml than those resulting from Densichek preparation. No significant differences in the standard deviations of the CFU counts were observed. The interoperator differences in standard deviations when dry flocked swabs were used decreased significantly compared to the differences when regular cotton swabs were used, whereas the mean of the standard deviations of all operators together was not significantly altered. In contrast, automated streaking significantly reduced both interoperator differences, i.e., the individual standard deviations, compared to the standard deviations for the manual method, and the mean of the standard deviations of all operators together, i.e., total methodological variation.

scholarly journals Erysipelothrix rhusiopathiae infection by geese to human transmission

2021 ◽  
Vol 14 (5) ◽  
pp. e240073
Author(s):  
Simone Martina Meier ◽  
Jan Kottwitz ◽  
Dagmar I Keller ◽  
Sarah Albini
Keyword(s):  
Case Report ◽  
Case History ◽  
Susceptibility Testing ◽  
Interdisciplinary Approach ◽  
Infectious Agent ◽  
Antibiotic Susceptibility Testing ◽  
Erysipelothrix Rhusiopathiae ◽  
Zoonotic Infection ◽  
Zoonotic Infections

Erysipelothrix rhusiopathiae transmission to human is often occupation-related, but in most cases, a detailed case history is missing. This case report is based on an interdisciplinary approach and includes a thorough medical record. A 58-year-old laboratory technician working on geese necropsy cut open her glove at a rib fragment of a goose and subsequently noticed a slowly progressive, reddish skin alteration in the particular region of the hand. Bacteriological investigations on the geese revealed septicaemia due to E. rhusiopathiae and therefore substantiated the diagnosis of the patient. The infectious agent could not be cultured from the patient; however, antibiotic susceptibility testing was performed using the goose isolate. An entire follow-up until full recovery of the patient was conducted. Zoonotic infections possibly have a significant impact on certain occupations. This case report analyses a rare but important zoonotic infection to create awareness of this in physicians caring for human patients.

Sign in / Sign up

Export Citation Format

Share Document